| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $190,048 | 7 | 78 |
Sells | $26,011 | 2 | 22 |
| Errico Thomas J. | director | 3 | $163,370 | 0 | $0 | $163,370 |
| Goldberger Daniel S | Chief Executive Officer | 3 | $17,660 | 0 | $0 | $17,660 |
| GANDOLFO JOHN P | director | 1 | $9,018 | 0 | $0 | $9,018 |
| Lev Joshua S. | Chief Financial Officer | 0 | $0 | 2 | $26,011 | $-26,011 |
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Over the last 12 months, insiders at electroCore, Inc. have bought $190,048 and sold $26,011 worth of electroCore, Inc. stock.
On average, over the past 5 years, insiders at electroCore, Inc. have bought $275,111 and sold $15,985 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Errico Thomas J. (director) — $163,370. Goldberger Daniel S (Chief Executive Officer) — $17,660. GANDOLFO JOHN P (director) — $9,018.
The last purchase of 1,000 shares for transaction amount of $4,840 was made by Goldberger Daniel S (Chief Executive Officer) on 2025‑12‑02.
| 2025-12-04 | Sale | Lev Joshua S. | Chief Financial Officer | 2,500 0.0319% | $5.05 | $12,625 | -2.63% | |
| 2025-12-02 | Goldberger Daniel S | Chief Executive Officer | 1,000 0.0127% | $4.84 | $4,840 | +2.11% | ||
| 2025-11-12 | Sale | Lev Joshua S. | Chief Financial Officer | 2,166 0.0287% | $6.18 | $13,386 | -19.55% | |
| 2025-08-11 | Goldberger Daniel S | Chief Executive Officer | 1,000 0.0129% | $4.23 | $4,230 | +15.31% | ||
| 2025-08-11 | Errico Thomas J. | director | 15,000 0.2051% | $4.47 | $67,050 | +15.31% | ||
| 2025-05-23 | GANDOLFO JOHN P | director | 1,800 0.0245% | $5.01 | $9,018 | +2.21% | ||
| 2025-05-12 | Errico Thomas J. | director | 10,000 0.1335% | $4.77 | $47,735 | +5.08% | ||
| 2025-03-17 | Goldberger Daniel S | Chief Executive Officer | 1,000 0.0145% | $8.59 | $8,590 | -37.17% | ||
| 2025-03-17 | Errico Thomas J. | director | 6,000 0.0818% | $8.10 | $48,585 | -37.17% | ||
| 2024-08-15 | Errico Thomas J. | director | 5,000 0.0788% | $6.12 | $30,595 | +23.37% | ||
| 2024-06-13 | GANDOLFO JOHN P | director | 1,000 0.0156% | $6.43 | $6,430 | +13.41% | ||
| 2024-06-05 | Goldberger Daniel S | Chief Executive Officer | 38,505 0.6218% | $6.43 | $247,587 | +8.45% | ||
| 2024-01-12 | POSNER BRIAN M | Chief Financial Officer | 16,000 – | $0 | $0 | +8.10% | ||
| 2023-09-15 | Goldberger Daniel S | Chief Executive Officer | 1,500 0.0246% | $5.55 | $8,333 | +8.14% | ||
| 2023-08-04 | Goldberger Daniel S | Chief Executive Officer | 50,000 – | $0 | $0 | +32.72% | ||
| 2023-08-02 | Goldberger Daniel S | Chief Executive Officer | 50,991 1.0559% | $4.35 | $221,811 | +37.90% | ||
| 2023-03-17 | Goldberger Daniel S | Chief Executive Officer | 500 0.011% | $3.43 | $1,715 | +72.80% | ||
| 2023-03-16 | Goldberger Daniel S | Chief Executive Officer | 500 0.0106% | $3.46 | $1,730 | +65.12% | ||
| 2023-03-15 | Goldberger Daniel S | Chief Executive Officer | 500 0.0108% | $3.55 | $1,775 | +63.22% | ||
| 2023-03-14 | Goldberger Daniel S | Chief Executive Officer | 500 0.011% | $3.73 | $1,865 | +59.13% |
| Goldberger Daniel S | Chief Executive Officer | 292565 3.6589% | $2.09M | 21 | 0 | +20.68% |
| Errico Thomas J. | director | 281401 3.5193% | $2.01M | 13 | 0 | <0.0001% |
| GANDOLFO JOHN P | director | 69087 0.864% | $493,281.18 | 4 | 0 | <0.0001% |
| Lev Joshua S. | Chief Financial Officer | 21667 0.271% | $154,702.38 | 0 | 2 | |
| Merck Global Health Innovation Fund, LLC | 10 percent owner | 3346032 41.8468% | $23.89M | 1 | 0 | <0.0001% |
| Errico Joseph P | director | 2724841 34.078% | $19.46M | 10 | 6 | +12.97% |
| TULLIS JAMES L L | director | 1764705 22.0701% | $12.6M | 3 | 0 | |
| Moody Trevor J | 423455 5.2959% | $3.02M | 3 | 0 | <0.0001% | |
| Amato Francis R. | Chief Executive Officer | 358831 4.4877% | $2.56M | 1 | 0 | <0.0001% |
| Staats Peter S. | Chief Medical Officer | 154636 1.9339% | $1.1M | 1 | 0 | <0.0001% |
| POSNER BRIAN M | Chief Financial Officer | 22437 0.2806% | $160,200.18 | 4 | 1 | <0.0001% |
| COX CARRIE SMITH | director | 21000 0.2626% | $149,940.00 | 3 | 0 | <0.0001% |
| Increased Positions | 12 | +34.29% | 33,279 | +2.83% |
| Decreased Positions | 11 | -31.43% | 460,824 | -39.12% |
| New Positions | 5 | New | 20,451 | New |
| Sold Out Positions | 6 | Sold Out | 360,850 | Sold Out |
| Total Postitions | 36 | +2.86% | 750,389 | -36.3% |
| Vanguard Group Inc | $1,062.00 | 2.92% | 233,473 | +1,140 | +0.49% | 2025-09-30 |
| Renaissance Technologies Llc | $456.00 | 1.25% | 100,286 | -80,400 | -44.5% | 2025-09-30 |
| International Assets Investment Management, Llc | $350.00 | 0.96% | 77,020 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $317.00 | 0.87% | 69,629 | +3,087 | +4.64% | 2025-09-30 |
| Jaffetilchin Investment Partners, Llc | $222.00 | 0.61% | 48,763 | +6,980 | +16.7% | 2025-09-30 |
| Wealthspire Advisors, Llc | $216.00 | 0.59% | 47,498 | 0 | 0% | 2025-09-30 |
| Hightower Advisors, Llc | $161.00 | 0.44% | 35,342 | 0 | 0% | 2025-09-30 |
| State Street Corp | $121.00 | 0.33% | 26,518 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $118.00 | 0.33% | 25,964 | -1,252 | -4.6% | 2025-09-30 |
| Two Sigma Investments, Lp | $112.00 | 0.31% | 24,603 | +4,231 | +20.77% | 2025-09-30 |